Four New Members Join Roche Scientific Advisory Board
Palo Alto, Calif., May 23, 2002 – Roche announced the appointment of four new members to the Roche Bioscience scientific advisory board in Palo Alto:
- Ronald T. Borchardt, Ph.D., of the University of Kansas-Lawrence. Borchardt obtained his Ph.D. in medicinal chemistry from the University of Kansas-Lawrence where he is a Solon E. Summerfield Distinguished Professor of Pharmaceutical Chemistry. His research interests are focused on the areas of drug design and drug delivery.
- William C. de Groat, Ph.D., of the University of Pittsburgh School of Medicine, is a professor in the Department of Pharmacology. He holds a Ph.D. in pharmacology from the University of Pennsylvania Medical School. He brings expertise in the design and implementation of drug discovery strategies for genitourinary diseases.
- Stephen I. Rennard, M.D., of the University of Nebraska Medical Center in Omaha, Neb., is a Larson Professor in the Department of Internal Medicine, professor in the Department of Pathology and Microbiology and director of the Nebraska Office of Tobacco Control and Research. He completed his M.D. at the Baylor College of Medicine in Houston, Texas. Dr. Rennard has clinical and research expertise in respiratory diseases.
- Douglas D. Richman, M.D., is director of the Research Center for AIDS and HIV Infection of the Veterans Affairs San Diego Healthcare System, professor at the University of California San Diego Departments of Pathology and Medicine, and director of the Center for AIDS research at the University of California in San Diego. Richman obtained his M.D. from the School of Medicine at Stanford University in Palo Alto, Calif.
The Roche Bioscience advisory board is comprised of internationally-recognized scientists with research and clinical expertise. The advisors review early research programs and provide critical evaluations and advice from an academic perspective.
"The addition of these four distinguished scientists and clinicians, will enable us to strengthen strategies in other diseases areas including HIV/AIDS, genitourinary diseases, and respiratory diseases," said James Woody, M.D., Ph.D., president, Roche Bioscience. In addition to the four new members, the board includes:
- John Bell, M.D., D.Phil., Clinical Immunology and Genetics, Oxford
- Lewis Judd, M.D., Mary Gilman Marston Professor and chair of the Department of Psychiatry for the University of California, San Diego School of Medicine
- E.J. Corey, Ph.D., Chemistry, Harvard University, Cambridge, Mass.
- Marc Feldmann, M.D., Ph.D., Kennedy Institute of Rheumatology, Sunley Division, Imperial College, England
- Larry Steinmann, M.D., professor of neurology at the Stanford University Medical Center
Greg L. Verdine, Ph.D., professor of chemical biology at Harvard University
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s premier research-based healthcare groups. With leading businesses in pharmaceuticals, diagnostics and vitamins, Roche offers a uniquely broad range of products and services that span prevention, diagnosis and treatment, thus enhancing health, well being and quality of life. Roche invests nearly 4 billion Swiss francs, or about $2.4 billion, annually in research and development. Its research focuses on significant unmet medical needs in the management of diseases of the central nervous system and genitourinary tract, metabolic disorders, inflammation, bone diseases, cancer, vascular diseases and virology. Roche employs approximately 7,000 people in research and development and has five global pharmaceutical research centers located in Basel, Switzerland; Kamakura, Japan; Penzburg, Germany; Nutley, N.J., and Palo Alto, Calif.
The 1000 women and men at the Roche Bioscience research center in Palo Alto, Calif. are focused on the discovery and early clinical development of innovative medicines to treat diseases in the following areas: arthritis, asthma and other respiratory diseases; anxiety, depression, schizophrenia and other neuropsychiatric diseases; genitourinary diseases, osteoporosis, HIV/AIDS, and hepatitis C.
Following are URLs for Roche on the web:
